CO2019004796A2 - Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina - Google Patents

Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina

Info

Publication number
CO2019004796A2
CO2019004796A2 CONC2019/0004796A CO2019004796A CO2019004796A2 CO 2019004796 A2 CO2019004796 A2 CO 2019004796A2 CO 2019004796 A CO2019004796 A CO 2019004796A CO 2019004796 A2 CO2019004796 A2 CO 2019004796A2
Authority
CO
Colombia
Prior art keywords
losartan
rosuvastatin
preparation
amlodipine
pharmaceutical complex
Prior art date
Application number
CONC2019/0004796A
Other languages
English (en)
Inventor
Ho Taek Im
Jae Hyun Park
Jong Soo Woo
Yong Il Kim
Hyuk Jun Cho
Sol Ee Lim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019004796(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CO2019004796A2 publication Critical patent/CO2019004796A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una preparación de complejo farmacéutica que incluye amlodipina, losartán y rosuvastatina como ingredientes activos. La preparación de complejo farmacéutica de la presente invención que incluye amlodipina, losartán y rosuvastatina como ingredientes activos presenta excelentes características de disolución de todos los ingredientes activos, y también tiene una estabilidad de preparación mejorada. Por lo tanto, la preparación de complejo de la presente invención se puede usar como un agente profiláctico o terapéutico para enfermedades cardiovasculares, que ha asegurado la estabilidad de la calidad incluso cuando se almacena durante un largo período de tiempo.
CONC2019/0004796A 2016-11-15 2019-05-10 Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina CO2019004796A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160152077 2016-11-15
PCT/KR2017/012703 WO2018093096A2 (en) 2016-11-15 2017-11-10 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin

Publications (1)

Publication Number Publication Date
CO2019004796A2 true CO2019004796A2 (es) 2019-05-21

Family

ID=62146632

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0004796A CO2019004796A2 (es) 2016-11-15 2019-05-10 Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina

Country Status (11)

Country Link
CO (1) CO2019004796A2 (es)
CR (1) CR20190265A (es)
DO (1) DOP2019000092A (es)
EA (1) EA201991190A1 (es)
EC (1) ECSP19040732A (es)
MX (1) MX2019005230A (es)
NI (1) NI201900048A (es)
PH (1) PH12019500779A1 (es)
SG (1) SG11201903132YA (es)
WO (1) WO2018093096A2 (es)
ZA (1) ZA201902720B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) * 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물

Also Published As

Publication number Publication date
WO2018093096A3 (en) 2018-07-26
PH12019500779A1 (en) 2019-07-29
CR20190265A (es) 2019-08-22
MX2019005230A (es) 2019-08-14
EA201991190A1 (ru) 2019-10-31
NI201900048A (es) 2019-10-11
WO2018093096A2 (en) 2018-05-24
ECSP19040732A (es) 2019-07-31
ZA201902720B (en) 2020-08-26
DOP2019000092A (es) 2019-09-30
SG11201903132YA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
PH12016502248A1 (en) Adenoassociated virus vectors for the treatment of lysosomal storage disorders
ECSP19038749A (es) Formulación de complejo farmacéutica que comprende amlodipina, losartán y clortalidona
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CL2017003437A1 (es) Formulación solida oral que contiene irinotecán y método de preparación de la misma
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
DOP2019000257A (es) Combinación farmacéutica que comprende ponesimod
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
DOP2019000015A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
CO2019004796A2 (es) Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
PH12016502527A1 (en) Stabilized desmopressin
UA98822U (en) APPLICATION OF KAPIKOR (MELDONIUM DIHYDRATE AND γ-BUTYROBETAINE DIHYDRATE) MEDICINE AS THE ENDOTHELIUM PROTECTOR WITH ANTI-ISCHEMIC EFFECT
UA100710U (xx) Застосування капсул "фітовенол" як гепатопротекторного засобу